商品信息

產(chǎn)品英文名稱	Mouse G-CSF protein
產(chǎn)品中文名稱	重組小鼠粒細(xì)胞集落刺激因子（G-CSF)
別名	G-CSF; Colony Stimulating Factor 3; Granulocyte; GCSF

商品屬性

標(biāo)簽	無標(biāo)簽
表達(dá)宿主	大腸桿菌
種屬	小鼠
序列	氨基酸序列來源于：重組小鼠粒細(xì)胞集落刺激因子（G-CSF) (P09920) (V31-A208) 表達(dá)的蛋白片段。
活性	通過其誘導(dǎo)M-NFS-60細(xì)胞增殖的能力來測(cè)定。ED50為2.038 pg/mL。
蛋白長(zhǎng)度	重組小鼠粒細(xì)胞集落刺激因子（G-CSF) 由178個(gè)氨基酸組成，預(yù)測(cè)分子量為18.95 KD。
純度	> 99% ，使用SDS-PAGE檢測(cè)
特點(diǎn)&優(yōu)勢(shì)	通過LAL法測(cè)定，每微克蛋白里內(nèi)毒素含量<1.0>
產(chǎn)品形式	凍干粉，凍干緩沖液為無菌的20 mM Tris，150 mM NaCl，pH 7.4。
基因ID	12985
蛋白序列鏈接	/uniprotkb/P09920/entry
使用中注意事項(xiàng)	開蓋使用前，請(qǐng)先離心。本產(chǎn)品為凍干粉，推薦用該產(chǎn)品配套的Reconstitution Buffer進(jìn)行復(fù)溶，且濃度不低于100 µg/mL。客戶可根據(jù)后續(xù)的實(shí)驗(yàn)需求，進(jìn)行進(jìn)一步的稀釋。
保存建議	本產(chǎn)品為凍干粉形式，建議：將凍干粉產(chǎn)品保存于-20℃以下的干燥環(huán)境中。本產(chǎn)品溶解之后，可在4℃保存2-7天，長(zhǎng)期使用請(qǐng)置于-20℃以下。為長(zhǎng)期保存，推薦添加載體蛋白（0.1% HAS/BSA或12%FBS），并酌情分裝保存，避免反復(fù)凍融。
運(yùn)輸條件	冰袋運(yùn)輸（藍(lán)冰）
警告	本文列出的產(chǎn)品僅供研究使用，不適用于人類或臨床診斷。我們產(chǎn)品所推薦應(yīng)用，不是建議使用我們的產(chǎn)品去違反任何或許可證。對(duì)于使用本產(chǎn)品可能發(fā)生的侵權(quán)或其他違規(guī)行為，我們不承擔(dān)任何責(zé)任。

附加信息

背景

Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins. It is produced by numerous cell types including immune and endothelial cells. G-CSF binding to its receptor G-CSF-R which belongs to the cytokine receptor type I family depends on the interaction of alpha-helical motifs of the former and two fibronectin type III as well as an immunoglobulin-like domain of the latter. Recent animal studies have also revealed that G-CSF activates multiple signaling pathways, such as Akt and also the Janus family kinase-2 and signal transducer and activation of transcription-3 (Jak2-STAT3) pathway, thereby promoting survival, proliferation, differentiation and mobilisation of haematopoietic stem and progenitor cells. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent. G-CSF prevents left ventricular remodeling after myocardial infarction by decreasing cardiomyocyte death and by increasing the number of blood vessels, suggesting the importance of direct actions of G-CSF on the myocardium rather than through mobilization and differentiation of stem cells. Accordingly, recombinant human (rh)G-CSF has been extensively used in clinical haematology and oncology to enable bone marrow transplantation or to treat chemotherapy-associated neutropenia. In preclinical study, G-CSF improved cardiac function and perfusion by angiomyogenesis and protection of cardiomyocytes in myocardial infarction.

圖片及說明